Detalles de la búsqueda
1.
Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination.
J Infect Dis
; 224(12): 2025-2034, 2021 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32502272
2.
Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial.
Int J Cancer
; 139(12): 2812-2826, 2016 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27541373
3.
Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women.
Int J Cancer
; 129(9): 2147-57, 2011 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21190190
4.
Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years.
Hum Vaccin
; 7(9): 958-65, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21892005
5.
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study.
Hum Vaccin
; 7(12): 1374-86, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22048171
6.
Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults.
Hum Vaccin Immunother
; 14(6): 1370-1377, 2018 06 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29461919
7.
Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults.
Vaccine
; 34(6): 863-8, 2016 Feb 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-26432913
8.
Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.
Vaccine
; 32(39): 5087-97, 2014 Sep 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-25018097
9.
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.
Hum Vaccin Immunother
; 10(12): 3455-65, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25483700
10.
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.
Hum Vaccin Immunother
; 10(8): 2147-62, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25424918
11.
Immunogenicity and safety of the candidate RTS,S/AS01 vaccine in young Nigerian children: a randomized, double-blind, lot-to-lot consistency trial.
Vaccine
; 32(48): 6556-62, 2014 Nov 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-25077418
12.
Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years.
J Adolesc Health
; 50(2): 187-94, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22265115
13.
Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial.
Pediatr Infect Dis J
; 30(12): e225-34, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21817954
14.
Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women.
J Adolesc Health
; 46(2): 142-51, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20113920
Resultados
1 -
14
de 14
1
Próxima >
>>